Boehringer Ingelheim has announced that they have finally settled on a dosage for their protease inhibitor, tipranavir. Now, larger Phase III clinical trials of the drug can begin. A recently completed Phase II study had compared three different dose combinations of tipranavir plus ritonavir given twice daily. A dosage of 500 mg tipranavir plus 200 mg ritonavir was chosen as providing the best balance of adequate viral suppression with the fewest side effects. The ritonavir acts to keep blood levels of tipranavir higher, longer, by slowing its metabolism through the liver.
The Phase II study was conducted in people with extensive experience using multiple drugs in all classes of antiretroviral therapy. Since tipranavir may be able to suppress multiple-PI resistant and wild type virus with about equal efficacy, it represents an urgently needed therapy for people who've run out of treatment options. Even though primary resistance to tipranavir itself seems to be slow to develop, people who still have an array of treatment choices probably won't choose tipranavir. Besides being a twice-a-day product, ritonavir boosted tipranavir is likely to raise blood lipid levels and cause drug interactions and tolerability problems. Unfortunately, these are factors that will also limit its use among some people who will desperately need it.
Having settled on a dose, Boehringer is now set to start up a pair of large Phase III trials. One study (RESIST 1) will be a 24-week trial in sites throughout North and South America, and Australia. A 16-week trial (RESIST 2) will be conducted exclusively in Europe. The time to approval of tipranavir will depend on how quickly the Phase III studies are enrolled, how much time the company needs to pull its data together for the FDA, and how long the FDA needs to review the application. Mid 2004 would be an optimistic guess.
Back to the GMHC Treatment Issues December 2002 contents page.